{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:31Z","timestamp":1788981571030,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JEIL Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01014-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:14:45Z","timestamp":1781108085000},"page":"539-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["JLP-2008 Fixed-Dose Combination Tablet Demonstrates Bioequivalence and Comparable Safety to Separate Dapagliflozin + Pioglitazone in Healthy Participants"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5509-0804","authenticated-orcid":false,"given":"Woo-lee","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonsuk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyounggyoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1682-1036","authenticated-orcid":false,"given":"Kwang Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilseob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-8089","authenticated-orcid":false,"given":"Anhye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"10397","key":"1014_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6.","journal-title":"Lancet"},{"key":"1014_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S319895","author":"J Reed","year":"2021","unstructured":"Reed J, Bain S, Kanamarlapudi V. A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes Metab Syndr Obes. 2021. https:\/\/doi.org\/10.2147\/DMSO.S319895.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1014_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00223-1","author":"E Di Angelantonio","year":"2023","unstructured":"Di Angelantonio E, et al. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol. 2023. https:\/\/doi.org\/10.1016\/S2213-8587(23)00223-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1014_CR4","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"14","author":"R Ruze","year":"2023","unstructured":"Ruze R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. https:\/\/doi.org\/10.3389\/fendo.2023.1161521.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1014_CR5","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1038\/s41598-024-54856-6","volume":"14","author":"A Pauli","year":"2024","unstructured":"Pauli A, de Mestral C, Marques-Vidal P. Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland. Sci Rep. 2024;14(1):4839. https:\/\/doi.org\/10.1038\/s41598-024-54856-6.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"1014_CR6","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care. 2022;46(Suppl 1):S140. https:\/\/doi.org\/10.2337\/dc23-S009.","journal-title":"Diabetes Care"},{"issue":"4","key":"1014_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13340-021-00495-5","volume":"12","author":"H \u0130nci","year":"2021","unstructured":"\u0130nci H. Evaluation of multiple drug use in patients with type 2 diabetes mellitus. Diabetol Int. 2021;12(4):399\u2013404. https:\/\/doi.org\/10.1007\/s13340-021-00495-5.","journal-title":"Diabetol Int"},{"issue":"11","key":"1014_CR8","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4103\/jfmpc.jfmpc_843_20","volume":"9","author":"S Kalra","year":"2020","unstructured":"Kalra S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: expert opinion from an international panel. J Fam Med Primary Care. 2020;9(11):5450\u20137. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_843_20.","journal-title":"J Fam Med Primary Care"},{"issue":"10","key":"1014_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887.","journal-title":"Circulation"},{"key":"1014_CR10","doi-asserted-by":"publisher","first-page":"155396","DOI":"10.1016\/j.metabol.2022.155396","volume":"140","author":"A Veelen","year":"2023","unstructured":"Veelen A, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023;140:155396. https:\/\/doi.org\/10.1016\/j.metabol.2022.155396.","journal-title":"Metabolism"},{"issue":"1","key":"1014_CR11","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1038\/s41598-019-41854-2","volume":"9","author":"F Alam","year":"2019","unstructured":"Alam F, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2019;9(1):5389. https:\/\/doi.org\/10.1038\/s41598-019-41854-2.","journal-title":"Sci Rep"},{"issue":"3","key":"1014_CR12","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1002\/edm2.70061","volume":"8","author":"U Khan","year":"2025","unstructured":"Khan U, et al. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a systematic review and meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab. 2025;8(3):e70061. https:\/\/doi.org\/10.1002\/edm2.70061.","journal-title":"Endocrinol Diabetes Metab"},{"key":"1014_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fendo.2018.00412","volume":"9","author":"E Han","year":"2018","unstructured":"Han E, et al. Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus. Front Endocrinol. 2018;9:412. https:\/\/doi.org\/10.3389\/fendo.2018.00412.","journal-title":"Front Endocrinol"},{"key":"1014_CR14","doi-asserted-by":"publisher","first-page":"110685","DOI":"10.1016\/j.diabres.2023.110685","volume":"200","author":"S-C Lo","year":"2023","unstructured":"Lo S-C, Kornelius E, Liao P-L, Huang J-Y, Yang Y-S, Huang C-N. Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract. 2023;200:110685. https:\/\/doi.org\/10.1016\/j.diabres.2023.110685.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2023","key":"1014_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/DDDT.S404182","volume":"17","author":"HC Kim","year":"2023","unstructured":"Kim HC, Lee S, Sung S, Kim E, Jang I-J, Chung J-Y. A comparison of the pharmacokinetics and safetyof dapagliflozin formate, an ester prodrug ofdapagliflozin, to dapagliflozin propanediolmonohydrate in healthy subjects. Drug Des Devel Ther. 2023;17(2023):1203\u201310. https:\/\/doi.org\/10.2147\/DDDT.S404182.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1014_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4333\/KPS.2009.39.2.133","volume":"39","author":"J-M Kang","year":"2009","unstructured":"Kang J-M, et al. Bioequivalence of Piros TM tablets to Actos TM tablets (pioglitazone HCl 15 mg). J Korean Pharm Sci. 2009;39(2):133\u20139. https:\/\/doi.org\/10.4333\/KPS.2009.39.2.133.","journal-title":"J Korean Pharm Sci"},{"issue":"2","key":"1014_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchromb.2006.05.032","volume":"843","author":"P Sripalakit","year":"2006","unstructured":"Sripalakit P, Neamhom P, Saraphanchotiwitthaya A. High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843(2):164\u20139. https:\/\/doi.org\/10.1016\/j.jchromb.2006.05.032.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"1014_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0731-7085(95)01665-1","volume":"14","author":"WZ Zhong","year":"1996","unstructured":"Zhong WZ, Williams MG. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction. J Pharm Biomed Anal. 1996;14(4):465\u201373. https:\/\/doi.org\/10.1016\/0731-7085(95)01665-1.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1014_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium\u2013glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13(1):47\u201354. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01314.x.","journal-title":"Diabetes Obes Metab"},{"issue":"20","key":"1014_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"W. M. Association","year":"2013","unstructured":"W. M. Association. Declaration of Helsinki. J Am Med Assoc. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"J Am Med Assoc"},{"key":"1014_CR21","unstructured":"MFDS. Korean Good Clinical Practice. https:\/\/www.mfds.go.kr. Accessed 30 June 2025."},{"key":"1014_CR22","unstructured":"European Medicines Agency. Assessment report, Pioglitazone ratiopharm European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-pioglitazone-ratiopharm_en.pdf. Accessed 30 June 2025."},{"issue":"3","key":"1014_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/pharmaceutics14030591","volume":"14","author":"J-W Park","year":"2022","unstructured":"Park J-W, et al. Pharmacokinetics of a fixed-dose combination product of Dapagliflozin and Linagliptin and its comparison with co-administration of individual tablets in healthy humans. Pharmaceutics. 2022;14(3):591. https:\/\/doi.org\/10.3390\/pharmaceutics14030591.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1014_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4333\/KPS.2009.39.3.217","volume":"39","author":"Y-J Lee","year":"2009","unstructured":"Lee Y-J, et al. One-step sample size determination for 2\u00d7 2 bioequivalence study. J Korean Pharm Sci. 2009;39(3):217\u20139. https:\/\/doi.org\/10.4333\/KPS.2009.39.3.217.","journal-title":"J Korean Pharm Sci"},{"issue":"4","key":"1014_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium\u2013glucose co\u2010transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(4):357\u201365. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01359.x.","journal-title":"Diabetes Obes Metab"},{"key":"1014_CR26","unstructured":"T. Pharmaceuticals. Actos (pioglitazone) package insert. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021073s049lbl.pdf. Accessed 30 June 2025."},{"key":"1014_CR27","unstructured":"U. S. FDA. Bioequivalence for Immediate-Release Solid Oral Dosage Forms. https:\/\/www.fda.gov\/media\/165049\/download. Accessed 30 June 2025."},{"issue":"5","key":"1014_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2217\/14750708.4.5.517","volume":"4","author":"H Sourij","year":"2007","unstructured":"Sourij H, Wascher TC. Pioglitazone in the management of type 2 diabetes and beyond. Therapy. 2007;4(5):517. https:\/\/doi.org\/10.2217\/14750708.4.5.517.","journal-title":"Therapy"},{"issue":"8","key":"1014_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","volume":"120","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713\u20139.","journal-title":"Am J Med"},{"issue":"2","key":"1014_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/pharmaceutics16020178","volume":"16","author":"CA Wilkins","year":"2024","unstructured":"Wilkins CA, Hamman H, Hamman JH, Steenekamp JH. Fixed-dose combination formulations in solid oral drug therapy: advantages, limitations, and design features. Pharmaceutics. 2024;16(2):178.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1014_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.4093\/dmj.2023.0314","volume":"48","author":"JH Heo","year":"2024","unstructured":"Heo JH, et al. Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: double-blind, randomized, placebo-controlled trial. Diabetes Metab J. 2024;48(5):937\u201348.","journal-title":"Diabetes Metab J"},{"key":"1014_CR32","unstructured":"U. S. FDA. ACTOS (pioglitazone) oral tablets label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021073s048lbl.pdf. Accessed 30 June 2025."},{"key":"1014_CR33","unstructured":"U. S. FDA. FARXIGA\u00ae(dapagliflozin) oral tablets label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293Orig1s022lbl.pdf. Accessed 30 June 2025."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01014-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01014-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:22Z","timestamp":1788980182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01014-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01014-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kwang Hyun Ahn is employed by the study sponsor but declares no conflicts of interest related to this study. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by both the Korean Ministry of Food and Drug Safety and the Institutional Review Board of CHA University, Bundang Medical Center (Seongnam, Korea; IRB no. CHAMC 2022-02-042). All procedures fol-lowed the ethical principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Korean Good Clinical Practice. The trial was retrospectively registered in the ClinicalTrials.gov (NCT06165965).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to any study-related procedures.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form (including individual details, images, or videos). Therefore, consent for publication was not required. This manuscript does not contain any individual person\u2019s identifiable data (including individual details, images, or videos). During the informed consent process for participation in the clinical trial, all participants were notified that study results may be published in a form that does not include personal information, and consent for such publication was obtained. Therefore, no additional consent to publish was required.","order":4,"name":"Ethics","label":"Consent to Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}